Dr Hussein Al-Ali

Hussein joined Anglia Ruskin University in November 2018 where he works as a research fellow. Hussein’s research focuses on assessing the efficacy of anticancer treatment in several cancer types including breast, lung, colorectal and ovarian cancers.

hussein.al-ali@anglia.ac.uk

Background

Prior to working at ARU, Hussein held the position of a research fellow at Brunel University London and had investigated how defects in DNA repair contribute to controlling the response to anticancer therapy. Moreover, Hussein also utilised imaging flow cytometry to identify and enumerate circulating tumour cells in patients’ blood.

Hussein currently works under the supervision of Professor Christopher Parris, exploring novel cancer therapeutic approaches.

Spoken Languages

English and Arabic

Research interests

• Cancer diagnosis and treatment

• Molecular biology

• Imaging Flow Cytometry

Qualifications

BSc Biomedical Sciences – Brunel University London (2012)

PhD – Brunel University London (2017)

Memberships, editorial boards

Member – Royal Society of Biology Associate

Fellow – Higher Education Academy

Selected recent publications

• Bourton, EC., Ahorner, PA., Plowman, PN., Zahir, SA., Al-Ali, H., Parris, CN. (2017) The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells. Journal of Cancer. October 23 (19): 4048-4056

• Parris, CN., Adam-Zahir, S., Al-Ali, H., Bourton, EC., Plowman, C., Plowman, PN. (2015) Enhanced -H2AX DNA damage foci detection using multi-magnification and extended depth of field in imaging flow cytometry. Journal of Cytometry, Part A. June 18 (8): 717-23.